Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroTech Medical (Hangzhou) Co., Ltd.
微泰醫療器械(杭州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2235)

VOLUNTARY ANNOUNCEMENT
OVERSEAS APPROVAL OF THE COMPANY'S CONTINUOUS GLUCOSE MONITORING SYSTEM

This announcement is published by MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of keeping the shareholders and potential investors of the Company informed of the latest development of the Group.

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company is pleased to announce that Our LinX (the international brand name of AiDEX X) continuous glucose monitoring system has recently received market approval in India for continuous dynamic glucose monitoring in adults. With its superior performance and reliability, the LinX system has not only been successfully included in the healthcare systems of many European countries, but has also gained access to a number of countries in emerging markets such as the Middle East, Asia Pacific and South America, building a diversified and sustainable support system for its international business.

In recent years, the global market for continuous glucose monitoring has shown strong growth momentum. As a core representative of emerging markets, India possesses vast market potential. According to the IDF's "Global Diabetes Atlas 2025", India has approximately 89.83 million people aged 20-79 with diabetes, representing a prevalence rate of 9.5%, ranking second globally in the number of people with diabetes and first globally in the number of diabetes-related deaths. Even more concerning is the increasing prevalence of prediabetes, which is showing a significant trend of affecting younger people. There are huge gaps in the prevention and control system, which creates an urgent and enormous demand for digital and intelligent diabetes management solutions.

The approval of our LinX continuous glucose monitoring system in India marks our successful entry into this strategically important, high-growth market. This initiative will greatly expand the Company's overseas market coverage, laying a solid foundation for the large-scale expansion of international business and revenue growth.

In the future, the Company will continue to focus on the global development of diabetes monitoring, treatment and management methods, and continuously promote technological and product innovation in related fields.

The Company reminds the investors that the production, sales and the resulting income of the above-mentioned product are affected by many factors such as market changes. Shareholders and potential investors of the Company are requested to exercise caution when dealing with the shares of the Company.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, November 26, 2025

As at the date of this announcement, the executive Directors of the Company are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors of the Company are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors of the Company are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.